News | March 18, 2022
AstraZeneca launches global R&D post-doctoral challenge
Successful proposals will secure fully funded postdoctoral research positions
Successful proposals will secure fully funded postdoctoral research positions
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
The focus is to build collaborative learning and sharing ecosystem
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Subscribe To Our Newsletter & Stay Updated
